December 25, 2014 3:11 AM ET


Company Overview of KAEL-GemVax Co., Ltd.

Company Overview

KAEL-GemVax Co., Ltd. develops and commercializes therapeutic cancer vaccines and infectious disease vaccines. It provides lung, melanoma, leukemia, pancreatic, prostate, and breast/ovarian cancer vaccines; and malaria, HIV, hepatitis, and influenza diseases vaccines. KAEL-GemVax Co., Ltd. was formerly known as GemVax Co., Ltd. The company was founded in 2001 and is based in Seongnam-si, South Korea. KAEL-GemVax Co., Ltd. operates as a subsidiary of GemVax & KAEL Co.,Ltd.

9th-10th Floor

939 Unjung-dong Bundang-gu

Seongnam-si,  463-440

South Korea

Founded in 2001


82 2 544 6221


82 2 3443 4997

Key Executives for KAEL-GemVax Co., Ltd.

Chief Executive Officer and President
Chief Executive Officer of US Emp
Age: 75
Senior Vice President
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Korea Vaccine Co., Ltd. Asia
Eisai Korea Inc. Asia
ST Pharm Co. Ltd. Asia
Jungwoo Pharmaceutical Co., Ltd. Asia
Korea Otsuka Pharmaceutical Co., Ltd. Asia

Recent Private Companies Transactions

January 20, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAEL-GemVax Co., Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at